This HTML5 document contains 70 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
wdthttp://www.wikidata.org/prop/direct/
wdtnhttp://www.wikidata.org/prop/direct-normalized/
schemahttp://schema.org/
rdfshttp://www.w3.org/2000/01/rdf-schema#
skoshttp://www.w3.org/2004/02/skos/core#
wikibasehttp://wikiba.se/ontology#
phttp://www.wikidata.org/prop/
n11http://dx.doi.org/10.1200/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n8http://rdf.ncbi.nlm.nih.gov/pubchem/reference/
xsdhhttp://www.w3.org/2001/XMLSchema#
wdshttp://www.wikidata.org/entity/statement/
wdhttp://www.wikidata.org/entity/

Statements

Subject Item
wd:Q83145997
rdf:type
wikibase:Item
schema:description
wetenschappelijk artikel наукова стаття, опублікована в грудні 2011 article scientifique publié en 2011 scientific article published on 27 December 2011 artículu científicu espublizáu n'avientu de 2011
p:P577
wds:Q83145997-C577EE51-9046-425D-B13E-AC7D7939B620
wdt:P577
2011-12-27T00:00:00Z
p:P2093
wds:Q83145997-A2937D65-33CA-4450-A53B-9C4BC8A69F28 wds:Q83145997-99FC3106-19FA-4BC0-93AB-ACA64C1F366D wds:Q83145997-7CA76D7A-12C3-43F7-8C82-24EFA51DAA10 wds:Q83145997-FBFB9A91-E50D-46F5-B78D-66DCB77EB0DE wds:Q83145997-DCE5DB8C-8958-4DB3-94E6-6F06A37735F6 wds:Q83145997-E0C77414-6C54-41F3-BCC7-ACAF76363439 wds:Q83145997-D612E419-5C4D-483D-BFBD-9E56F3877BA0 wds:Q83145997-367C60DD-4031-4E3E-95BE-E2868059B61D wds:Q83145997-00BC2996-27FD-49A6-B2E7-932FA0253BA9 wds:Q83145997-6F7AEFD5-CF69-4F52-873F-B911B63F721A wds:Q83145997-70AEF938-0B5D-4D42-B22C-D5E0B6879F05 wds:Q83145997-58957EF4-9630-4DE2-9BEC-B5160FA10C4D wds:Q83145997-5F9AFC31-30F6-426A-80EF-F430E9673E57
wdt:P2093
Mark Wickens James Carmichael Elizabeth S Lowe Bella Kaufman Katherine M Bell-McGuinn Joo Ern Ang Charlie Gourley Beth Y Karlan Stan B Kaye Tamar Safra Amit Amnon Lee-May Chen Michael Friedlander
rdfs:label
Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer
skos:prefLabel
Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer
schema:name
Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer
p:P50
wds:Q83145997-E14992D0-6E20-4C74-82E8-6A8A8EB85C9E wds:Q83145997-A59F0D26-FA0F-4444-99FA-5B52F77E7A13 wds:Q83145997-9641DD7B-1785-453A-A419-98130ACADF9B
wdt:P50
wd:Q116996864 wd:Q11718282 wd:Q89808263
p:P1476
wds:Q83145997-27EEFF28-134B-4022-83C2-25E08130BFB3
wdt:P1476
Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer
p:P304
wds:Q83145997-6104A207-A550-4E5A-899D-0E3544ACF993
wdt:P304
372-379
p:P31
wds:Q83145997-C3859064-A395-4AA2-9200-E69EF45475BB
wdt:P31
wd:Q13442814
p:P921
wds:Q83145997-3CD142FD-3B82-4D9B-81D3-29D5866C9737 wds:Q83145997-EE442682-B9B5-49D5-9A08-F77DF1D01161 wds:Q83145997-EE871253-3FEC-4B81-805F-6482A26C1DDA
wdt:P921
wd:Q7083106 wd:Q172341 wd:Q18936
p:P698
wds:Q83145997-D54FEA2B-7873-43C2-B967-1C6957996F4B
wdtn:P698
n8:22203755
wdt:P698
22203755
p:P1433
wds:Q83145997-0A9B3DB7-F9F7-4D39-8363-749D78A87BA8
wdt:P1433
wd:Q400292
p:P433
wds:Q83145997-941CEF8D-1BAB-44DD-B6AF-BC415C8212DE
p:P478
wds:Q83145997-5FBC8498-D141-4B03-965D-B5673F17D00D
wdt:P433
4
wdt:P478
30
p:P356
wds:Q83145997-5726D744-192D-4879-A105-831D9E6D073C
wdtn:P356
n11:JCO.2011.36.9215
wdt:P356
10.1200/JCO.2011.36.9215